Acute Porphyria Drugs

J07BN04 - Covid-19, Protein Subunit

Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the protein subunit Covid-19 vaccine, no porphyrinogenic effects are expected.
Chemical description
Protein subunit vaccine.
Therapeutic characteristics
Indicated for preventing coronavirus disease 2019 (COVID-19) in individuals aged 12 years and older. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BN or go back.
References
# Citation details PMID
*Government bodies
1. European Medicines Agency (EMA). SmPC Nuvaxovid.
2. Norwegian institute of public health. Vaccines and vaccination.

Tradenames

Bimervax · Nuvaxovid Bimervax · Nuvaxovid Bimervax · Nuvaxovid · Vidprevtyn Beta Bimervax · Nuvaxovid Bimervax · Nuvaxovid Bimervax · Nuvaxovid Nuvaxovid Bimervax · Nuvaxovid Bimervax · Nuvaxovid Bimervax · Nuvaxovid Nuvaxovid Bimervax · Nuvaxovid Bimervax · Nuvaxovid · Vidprevtyn Beta Nuvaxovid · VidPrevtyn Nuvaxovid · VidPrevtyn Beta Vaccines
In cooperation with Ipnet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙